Drug profile · INN
spirapril hydrochloride
RENORMAX
spirapril hydrochloride (RENORMAX) is a angiotensin-converting enzyme inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — spirapril hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
spirapril hydrochloride (RENORMAX) is a angiotensin-converting enzyme inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Angiotensin-converting enzyme inhibitor
Primary target: Angiotensin-converting enzyme
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is spirapril hydrochloride?
spirapril hydrochloride (RENORMAX) is a angiotensin-converting enzyme inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for spirapril hydrochloride?
RENORMAX is a marketed brand name for spirapril hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of spirapril hydrochloride?
spirapril hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.